Plain-English translation of NCT05647564 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study uses two types of imaging scans — called FDG PET/CT and PSMA PET/CT — to help researchers understand why advanced prostate cancer sometimes stops responding to second-generation hormone-blocking medications like enzalutamide, abiraterone, darolutamide, or apalutamide. The scans will help doctors see what's happening inside your body when the medication stops working. You'll have 6 scans total over the course of the study.
Some men with advanced prostate cancer respond well to hormone-blocking treatment at first, but then the cancer starts growing again even while they're still taking the medication. Doctors don't fully understand why this happens. This study aims to use advanced imaging to spot early signs of treatment resistance, which could help doctors make better treatment decisions in the future.
You likely qualify if…
You likely don't qualify if…
Depending on which group you join, you'll either be starting a new hormone-blocking medication or you're already taking one and showing signs it's no longer working. You'll come in for 6 imaging appointments over time — 3 using one type of scan and 3 using another type. Each scan takes about 30 minutes, during which you'll lie flat while the machine takes detailed pictures. The scans themselves are painless and non-invasive. Your doctor will use these images to better understand what's happening with your cancer.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States